| pubmed-article:15757596 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C1522318 | lld:lifeskim |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C1948041 | lld:lifeskim |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C0168273 | lld:lifeskim |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C0522523 | lld:lifeskim |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C0565990 | lld:lifeskim |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:15757596 | lifeskim:mentions | umls-concept:C1280519 | lld:lifeskim |
| pubmed-article:15757596 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15757596 | pubmed:dateCreated | 2005-3-10 | lld:pubmed |
| pubmed-article:15757596 | pubmed:abstractText | A recent large-scale, randomized trial demonstrated the noninferiority of a strategy of bivalirudin with provisional glycoprotein (GP) IIb/IIIa inhibition compared with routine GP IIb/IIIa inhibition. There is a paucity of outcome data with bivalirudin use in the setting of real-world experience. We evaluated 6,996 patients who underwent percutaneous coronary intervention between January 2001 and December 2004 to compare early and late outcomes with a bivalirudin-based antithrombotic regimen with those with a heparin-based regimen. Propensity adjustment was performed to correct for baseline differences in patient characteristics. Bivalirudin-based therapy was used in 1,070 patients, heparin only in 801 patients, and heparin plus GP IIb/IIIa inhibitors in 5,125 patients. Compared with patients who received heparin or those who received heparin plus GP IIb/IIIa inhibitors, patients who received bivalirudin had lower incidences of bleeding (blood transfusion rate 1.7% vs 4.0%, p <0.001) and periprocedural myonecrosis (creatine kinase-MB >5 times the upper limit of normal 2.7% vs 4.3%, p = 0.016). Differences in bleeding end points remained significant after adjusting for the propensity to receive bivalirudin, but there was no difference in ischemic events. There was no difference in unadjusted long-term survival rate (log-rank test p = 0.46, total number of deaths 412, mean follow-up 17 months) or in propensity-adjusted long-term survival rate (hazard ratio 1.37, 95% confidence interval 0.90 to 2.08, p = 0.14). Compared with heparin with or without GP IIb/IIIa inhibition, the use of bivalirudin in a large consecutive patient registry at a tertiary care center was associated with fewer bleeding events and no evident increase in the incidence of ischemic complications. | lld:pubmed |
| pubmed-article:15757596 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15757596 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15757596 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15757596 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15757596 | pubmed:issn | 0002-9149 | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:BhattDeepak... | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:EllisStephen... | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:TopolEric JEJ | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:LincoffA... | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:GurmHitinder... | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:YadavJay SJS | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:FathiRobertR | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:RajagopalVive... | lld:pubmed |
| pubmed-article:15757596 | pubmed:author | pubmed-author:VivekanathanD... | lld:pubmed |
| pubmed-article:15757596 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15757596 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:15757596 | pubmed:volume | 95 | lld:pubmed |
| pubmed-article:15757596 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15757596 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15757596 | pubmed:pagination | 716-21 | lld:pubmed |
| pubmed-article:15757596 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:meshHeading | pubmed-meshheading:15757596... | lld:pubmed |
| pubmed-article:15757596 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15757596 | pubmed:articleTitle | Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. | lld:pubmed |
| pubmed-article:15757596 | pubmed:affiliation | Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. | lld:pubmed |
| pubmed-article:15757596 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15757596 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15757596 | lld:pubmed |
